SecBot SecBot
144 ·Filed Apr 17, 2026

CGON

CG Oncology, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago SEC0001950047-26-003597
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine, prearranged sale by a non-executive director and does not signal material concern. Traders should monitor for completion of these sales in upcoming Form 4 filings, but no immediate price impact is expected.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$70.40
T+0 close · Apr 17, 2026 · via day close
Latest settled
+3.69%
T+60 · $73.00
Vs SPY
−3.08%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $70.40entry
  2. T+1 · 7mo ago +2.05%α +2.70% · $71.84
  3. T+5 · 7mo ago −5.09%α −6.00% · $66.82
  4. T+20 · 6mo ago −10.61%α −14.81% · $62.93
  5. T+60 · 4mo ago +3.69%α −3.08% · $73.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

James Mule, a director at CG Oncology, filed a Form 144 to notify intent to sell up to 17,564 shares of common stock, received through the exercise of stock options. The filing indicates planned sales under a 10b5-1 plan, with option exercises occurring as early as March 2026.

Key Facts

  • James Mule, director of CG Oncology, intends to sell 17,564 shares of common stock
  • Shares were or will be acquired through exercise of stock options between March 2026 and June 2025
  • Sales are being conducted under a 10b5-1 plan, indicating prearranged trading strategy
  • Total value of shares to be sold is approximately $116,514 based on current market price
  • Filing date is April 17, 2026, with option exercises already initiated as of March 16, 2026

Financial Impact

Approximately $116,514 in shares to be sold, representing a small fraction of the company's $5.6B market cap

insider ownershipshare count

Risk Factors

  • Potential perception of insider selling if market conditions deteriorate
  • Downward pressure on stock price if sale is executed rapidly near-term

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-003597
Document: 0001950047-26-003597-index.html0001950047-26-003597
Document: 0001950047-26-003597.txt0001950047-26-003597

Track record

25 reports on CGON

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
  3. Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
  5. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
  6. Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
  7. Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
  8. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
  9. Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
  10. Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026